Center for Translational Research Sweden
Karin Meyer, PhD, is currently the CEO of the Center for Translational Research Sweden and a Member of the Management Board at WHO Uppsala Monitoring Center. Karin has a wealth of experience serving as a Board Member for Smartfish AS, Nordic Nanovector AS, Kårhuset Pharmen AB, NEPI Foundation, and as the CEO of the Swedish Pharmaceutical Society. Karin also has a background in business development and management, having held titles such as Deputy General Director & Senior Business Developer at Uppsala University Innovation/Uppsala University Holding Company and Managing Director of Quintiles Scandinavia/Innovex AB. Additionally, Karin has a strong academic background, with a PhD in Pharmacology from Uppsala University and post-doctoral fellowship from UCLA.
This person is not in any teams
Center for Translational Research Sweden
Center for Translational Research Sweden AB (CTR) is the holding company for an expanding group of clinical research organisations (CROs) engaged in translational research. Currently, CTR has seven subsidiaries supporting e.g. the pharmaceutical and medical technology industry: CTC Clinical Trial Consultants AB, Lablytica Life Science AB, RegSmart Life Science AB, RegFile AB, Toxicology Knowledge Team Sweden AB, MetaSafe AB, QAlliance AB and CTC Netherlands. Together the companies offer a wide range of services including regulatory support, bioanalysis and full service clinical conduct and management through all stages of product development. CTR´s vision is to be a leading and sustainable translational research organization having the critical mass of resources in terms of necessary expert competencies and financial stability to support our national and international life science customers to bring improved treatments to the market for the benefit of suffering patients.